Mucosis Announces Positive Proof-Of-Concept Data for Mimopath Platform In Humans

Mucosis, in conjunction with the Centre for Human Drug Research, conducted the clinical trial to assess the safety, tolerability, and immunogenicity of nasally administered FluGEM.

Dutch vaccine development company Mucosis B.V. has announced Phase I clinical data providing proof-of-concept that Mimopath?-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract.

Mucosis, in conjunction with the Centre for Human Drug Research (CHDR; Leiden, the Netherlands), conducted the clinical trial to assess the safety, tolerability, and immunogenicity of nasally administered FluGEM?, a Mimopath?-based mucosal influenza vaccine containing bacterium-like particles (BLPs) in addition to a standard amount of trivalent split influenza antigen. This Phase I study, which began in March of 2011, was a randomized, blinded, placebo-controlled study and enrolled 60 human subjects 18 to 49 years of age who received either standard amounts of trivalent split influen